All In Biotech

Drug Trial Radar · NCT06998056

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

101

Actual

Start

Jun 9, 2025

Primary completion

Dec 4, 2025

Study completion Dec 4, 2025

Sponsor

Lead sponsor
Arcutis Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 months, up to 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Conditions

  • Atopic Dermatitis (Eczema)

Interventions

  • ARQ-151 cream 0.05%Drug

    ARQ-151 Cream 0.05% is applied once daily for 4 weeks in infants with atopic dermatitis (eczema).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subject incidence of adverse eventsTime frame: 4 weeks
  2. Subject incidence of serious adverse eventsTime frame: 4 weeks
  3. Incidence of application site reactionsTime frame: 4 weeks

Locations

22 sites in 3 countries. Site status is shown where the registry gives one.

  • Arcutis Clinical Study Site 208

    Birmingham, Alabama

  • Arcutis Clinical Study Site 221

    Bryant, Arkansas

  • Arcutis Clinical Study Site 214

    Fountain Valley, California

  • Arcutis Clinical Study Site 209

    Rancho Santa Margarita, California

  • Arcutis Clinical Study Site 207

    Coral Gables, Florida

  • Arcutis Clinical Study Site 217

    Delray Beach, Florida

  • Arcutis Clinical Study Site 213

    Jacksonville, Florida

  • Arcutis Clinical Study Site 223

    Boise, Idaho

  • Arcutis Clinical Study Site 219

    West Lafayette, Indiana

  • Arcutis Clinical Study Site 212

    Minneapolis, Minnesota

  • Arcutis Clinical Study Site 211

    Portsmouth, New Hampshire

  • Arcutis Clinical Study Site 220

    Mason, Ohio

  • Arcutis Clinical Study Site 206

    Portland, Oregon

  • Arcutis Clinical Study Site 222

    Summerville, South Carolina

  • Arcutis Clinical Study Site 210

    Bellaire, Texas

  • Arcutis Clinical Study Site 224

    Fort Worth, Texas

  • Arcutis Clinical Study Site 202

    San Antonio, Texas

  • Arcutis Clinical Study Site 203

    Winnipeg, Manitoba, Canada

  • Arcutis Clinical Study Site 204

    Halifax, Nova Scotia, Canada

  • Arcutis Clinical Study Site 216

    Waterloo, Ontario, Canada

  • Arcutis Clinical Study Site 225

    Saskatoon, Saskatchewan, Canada

  • Arcutis Clinical Study Site 201

    Santo Domingo, Dominican Republic

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.